Back to results
US 12,274,748 B2Granted
Adenoviral vector transduced apheresis product
AssigneeImmunityBio, Inc.
InventorsPatrick Soon-Shiong, Elizabeth Gabitzsch, Philip T. Liu
Life of this patent
Estimating the term…
Abstract
An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.
Claims6
An immunotherapeutic composition, comprising:
- 1) Subject-derived peripheral blood mononuclear cells (PBMC), granulocyte macrophage colony stimulating factor (GM-CSF), and FMS-like tyrosine kinase 3 (Flt-3) ligand,
- 2) at least one recombinant adenovirus subtype 5 (Ad5) vector comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, and
- 2) Immune-stimulating cytokines comprising a) Interleukin-15 (IL-15) or an IL-15:
- IL-15 receptor alpha (IL15:
- IL15Rα) complex, b) IL-2, and c) IL-7,
- wherein the PBMC are simultaneously exposed to the Ad5 vector and the immune stimulating cytokines.
3 more elements
Dependencies are inferred from the claim text.